Multifocal Lens
Multifocal Contact Lenses for Near-sightedness
This trial aims to compare the vision performance between two different contact lenses, NaturalVue Multifocal and MiSight, by testing various aspects such as clarity, reading ability, contrast sensitivity, and depth
Procedure
One-Week Contact Lenses for Near-Sightedness
This trial will test the comfort and effectiveness of switching current Acuvue Oasys wearers to one-week reusable contact lenses. Participants will wear the new lenses for about 2 weeks and provide feedback
Procedure
Violet Light Therapy for Near-Sightedness
This trial uses special violet light lamps to see if they can help slow down the worsening of nearsightedness in children. The study compares these lamps to regular white light lamps, focusing on their effects over time.
Popular Filters
Trials for Near-sightedness Patients
Behavioural Intervention
Red-light Therapy for Near-sightedness
This trial showed that 3 minutes of low-level red-light technology twice a day can control 87.7% of myopia progression and 76.8% of axial length elongation. This could be a potential global solution for myopia control.
Contact Lens
MiSight 1 Day Contact Lenses for Nearsightedness
This trial is testing special contact lenses called MiSight 1 Day to see if they can slow down worsening nearsightedness in children. The study will also check if the benefits last after stopping the treatment. The lenses work by changing how light enters the eye to slow down eye growth. MiSight 1 Day contact lenses have been shown to slow myopia progression in children over several years.
Trials With No Placebo
Behavioural Intervention
Red-light Therapy for Near-sightedness
This trial showed that 3 minutes of low-level red-light technology twice a day can control 87.7% of myopia progression and 76.8% of axial length elongation. This could be a potential global solution for myopia control.
Contact Lens
MiSight 1 Day Contact Lenses for Nearsightedness
This trial is testing special contact lenses called MiSight 1 Day to see if they can slow down worsening nearsightedness in children. The study will also check if the benefits last after stopping the treatment. The lenses work by changing how light enters the eye to slow down eye growth. MiSight 1 Day contact lenses have been shown to slow myopia progression in children over several years.
Frequently Asked Questions
Introduction to myopia
What are the top hospitals conducting myopia research?
When it comes to advancing the understanding and treatment of myopia, several hospitals are leading the way. In Pittsburgh, Kannarr Eye Care is at the forefront with four ongoing myopia trials and a total of nine completed trials. Since their first recorded myopia trial in 2016, they have been dedicated to finding innovative solutions for this common vision condition. Similarly, Bellaire Family Eye Care in Bellaire has also made significant contributions despite being relatively new to research in this field. With four active myopia trials and a promising start in 2022, they are committed to making strides towards addressing myopia.
In Sioux Falls, Vance Thompson Vision is another notable hospital focusing on myopia research. They currently have three ongoing clinical trials and a respectable track record of five previous studies since their inaugural trial back in 2012. Meanwhile, Golden Optometric Group in Whittier has been actively involved with three active myopia trials as part of their comprehensive approach to eye care. Their commitment dates back to 2013 when they first embarked on conducting studies related to this refractive error.
Finally, Advanced Eyecare PC based in Raytown joins these esteemed institutions by actively participating in three current myopia trials while having conducted an additional five investigations since recording their first trial for this condition in 2019.
These hospitals across different locations demonstrate a shared dedication towards combating the growing prevalence of myopia worldwide through innovative clinical research efforts. By working together and exploring various approaches within these studies for better management or potential cure options we can look forward towards achieving improved outcomes that will benefit individuals affected by this widespread vision disorder globally
Which are the best cities for myopia clinical trials?
Chicago, Illinois; New york, New York; and Memphis, Tennessee emerge as the top cities for myopia clinical trials. All three locations currently have 7 active trials investigating various treatments such as MiSight 1 Day, Atropine 0.01% Ophthalmic Solution, Multifocal contact lenses, Novel spectacle lens design, and more. These cities offer individuals with myopia access to cutting-edge research that could potentially lead to improved treatments and management strategies for this condition.
Which are the top treatments for myopia being explored in clinical trials?
Myopia, or nearsightedness, is a common vision problem that researchers are actively working to address through innovative treatments. Among the top contenders explored in clinical trials are:
- Novel spectacle lens design: Currently being tested in three active trials and garnering interest since 2018 with five all-time myopia trials.
- MiSight 1 Day: This promising treatment has sparked curiosity with two ongoing trials. It was first listed in 2022 and already shows potential for managing myopia.
- Wavefront-guided LASIK: Although still in its early stages of exploration, this technique holds promise as demonstrated by one current trial. Its first listing occurred only recently, also in 2022.
- EVO ICL: Another newcomer to the myopia scene, EVO ICL is undergoing evaluation through one active trial since its introduction this year.
These cutting-edge approaches aim to enhance our understanding and broaden treatment options for individuals living with myopia.
What are the most recent clinical trials for myopia?
Exciting progress is being made in the field of myopia treatment, with recent clinical trials offering hope for those affected by this condition. One promising study involves the use of atropine to address myopia, reaching Phase 2 and becoming available as a potential intervention on 4/20/2023. Additionally, OT-101 Ophthalmic Solution has advanced to Phase 3 and became accessible on 4/1/2021 as a potential solution for myopia. Another noteworthy trial is EXP039, which reached both Phase 1 and Phase 2 stages, becoming available on 12/1/2020. These ongoing investigations signify significant strides towards understanding and managing myopia effectively.
What myopia clinical trials were recently completed?
Two notable clinical trials for myopia have recently concluded, bringing new insights into the treatment of this prevalent condition. In May 2022, Ohio State University wrapped up a trial evaluating the efficacy of 0.01% atropine, while in June 2018, the Jaeb Center for Health Research completed their own investigation into Atropine. These studies contribute to our understanding of potential therapeutic options and shed light on ways to address myopia.